CAS 2361659-61-0

AES-135

CAS: 2361659-61-0

AES-135 is a potent HDAC inhibitor, inhibits HDAC3, HDAC6, HDAC11 (IC50s: 654, 190, and 636 nM) with anti-tumor activity.

Formula: C₃₃H₂₉F₆N₃O₅S

Purity: 97.72%

Color and Shape: Solid

Molecular weight: 693.66

Ref: TM-T10255

AES-135

CAS: 2361659-61-0

AES-135

Purity: ≥95%

Molecular weight: 693.66g/mol

Ref: 54-BUP02393

AES-135

CAS: 2361659-61-0

AES-135 is a hydroxamic acid that inhibits histone deacetylase (HDAC). It has been shown to be effective in treating cancer cells. AES-135 binds to HDACs and prevents them from removing acetyl groups from lysine residues on histones, which prevents the transcription of genes. This drug has been shown to inhibit the growth of pancreatic cancer cells in culture, but it is not known if this effect occurs in humans. A phase I clinical trial with AES-135 was conducted in patients with pancreatic cancer, but the results were inconclusive. Preclinical studies have shown that this drug can be used as a treatment for breast cancer, leukemia, and other cancers.

Formula: C₃₃H₂₉F₆N₃O₅S

Purity: Min. 95%

Molecular weight: 693.7 g/mol

Ref: 3D-LUD65961